Gyre Therapeutics, Inc. (GYRE)
(Delayed Data from NSDQ)
$13.51 USD
-0.22 (-1.60%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $13.43 -0.08 (-0.59%) 5:18 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Balance Sheet
Fiscal Year End for Gyre Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 34 | 22 | 47 | 79 | 77 |
Receivables | 17 | 5 | 2 | 3 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 3 | 7 | 4 |
Total Current Assets | 57 | 28 | 51 | 90 | 96 |
Net Property & Equipment | 23 | 0 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 3 | 0 |
Other Non-Current Assets | 5 | 0 | 0 | 0 | 0 |
Deferred Charges | 5 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 24 | 0 | 0 | 1 | 0 |
Total Assets | 117 | 28 | 56 | 95 | 99 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 6 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 4 | 6 | 9 | 9 |
Income Taxes Payable | 5 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 13 | 0 | 2 | 15 |
Total Current Liabilities | 20 | 17 | 14 | 18 | 29 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 17 | 15 | 19 | 30 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 65 | 33 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 68 | 389 | 444 | 391 | 327 |
Retained Earnings | -86 | -411 | -403 | -315 | -259 |
Other Equity | 31 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 78 | 12 | 41 | 76 | 68 |
Total Liabilities & Shareholder's Equity | 117 | 28 | 56 | 95 | 99 |
Total Common Equity | 14 | -22 | 41 | 76 | 68 |
Shares Outstanding | 76.60 | 2.10 | 2.10 | 1.40 | 0.80 |
Book Value Per Share | 0.18 | -10.33 | 19.57 | 54.34 | 85.43 |
Fiscal Year End for Gyre Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 25 | 37 | 34 | 2 | 7 |
Receivables | 20 | 17 | 17 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 5 | 4 | 0 | 0 |
Other Current Assets | 3 | 4 | 3 | 2 | 1 |
Total Current Assets | 54 | 63 | 57 | 5 | 8 |
Net Property & Equipment | 24 | 24 | 23 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 5 | 5 | 5 | 5 |
Deferred Charges | 5 | 5 | 5 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 0 | 0 |
Deposits & Other Assets | 30 | 24 | 24 | 0 | 0 |
Total Assets | 121 | 122 | 117 | 10 | 12 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 11 | 12 | 2 | 3 |
Income Taxes Payable | 2 | 6 | 5 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 0 | 0 |
Total Current Liabilities | 16 | 19 | 20 | 2 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 11 | 18 | 5 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 33 | 38 | 6 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 65 | 33 | 33 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 134 | 133 | 68 | 385 | 385 |
Retained Earnings | -74 | -78 | -86 | -415 | -413 |
Other Equity | 34 | 33 | 31 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 93 | 89 | 78 | 4 | 5 |
Total Liabilities & Shareholder's Equity | 121 | 122 | 117 | 10 | 12 |
Total Common Equity | 93 | 89 | 14 | -30 | -28 |
Shares Outstanding | 85.50 | 85.40 | 76.60 | 2.50 | 2.50 |
Book Value Per Share | 1.09 | 1.04 | 0.18 | -11.92 | -11.32 |